Notable Labs (NTBLQ) AI Stock Analysis

• Market Cap: $966.00
• Dividend Yield: N/A
• Average Volume (3M): 50.33K
• Price to Earnings (P/E): ―
• Beta (1Y): -38.36
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 9,659,496
• 10 Day Avg. Volume: 43,656
• 30 Day Avg. Volume: 50,326
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 30 Underperform
• Price Target: ―

Notable Labs is currently in a challenging position with significant financial performance issues, including ongoing losses and negative cash flows. Technical analysis reflects bearish sentiment, and the valuation is unattractive due to a negative P/E ratio. The substantial decline in stock price following the recent earnings announcement underscores market concern. Despite potential growth within the biotechnology sector, significant improvements in financial health are needed.

Positive Factors

Clinical Development

Notable Labs kicked off the volasertib AML trial with an accelerated clinical program moving directly into the Predictive Precision Medicines Platform-selected Phase 2 trial.

Innovation and Technology

Notable Labs' ability to now use cryopreserved samples with its Predictive Precision Medicines Platform unlocks significant data sources.

Regulatory Progress

NTBL was cleared for the Phase 2 volasertib program by the FDA and intends to enroll patients.

Negative Factors

Financial Health

The company had a 2Q-end cash balance of $4.1M, and the estimated current cash balance is approximately $2M.

Operational Challenges

Notable Labs is conserving cash by pausing the planned volasertib Phase 2 trial and reducing workforce and consultants by 65%.

Uncertainty in Product Development

The future of lead asset volasertib is unclear.

Notable Labs Business Overview & Revenue Model

Company Description

Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.

How the Company Makes Money

Notable Labs generates revenue primarily through partnerships and collaborations with pharmaceutical companies and research institutions. The company offers its platform as a service to these partners, who use it to screen and identify promising drug candidates more efficiently. Additionally, Notable Labs may engage in licensing agreements, allowing partners to use its technology in exchange for fees or royalties. The company's business model is heavily reliant on its ability to form strategic alliances and demonstrate the value of its platform in accelerating drug development.

Notable Labs Financial Statement Overview

Summary

Notable Labs faces significant financial challenges, with ongoing losses and cash flow issues. While there are signs of revenue growth and manageable debt levels, the company must address its profitability and cash generation to improve its financial health. The biotechnology industry context suggests potential for growth, but financial stability remains a concern.

Income Statement

Notable Labs has faced significant challenges in its income statement, with consistent losses over the years. Gross profit margin is positive, but the company is struggling with negative net income and EBIT margins. Revenue has shown volatility, with a significant increase in the latest period, but profitability remains a concern.

Balance Sheet

The balance sheet shows some improvement, with positive stockholders' equity and manageable total debt. However, high liabilities compared to assets and fluctuating equity levels pose risks. The debt-to-equity ratio is relatively low, reflecting limited leverage, but overall financial stability is moderate.

Cash Flow

Cash flow analysis reveals consistent negative operating and free cash flows, indicating challenges in generating cash from operations. The company has relied on financing to support its cash position. The ratio of operating cash flow to net income is less favorable, reflecting ongoing cash management issues.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
―	―	―	―	―
	Gross Profit
113.00K	8.00K	403.00K	528.00K	340.00K
	EBIT
-14.66M	-12.92M	-30.00M	-24.48M	-20.08M
	EBITDA
-14.40M	-12.60M	-16.59M	-22.92M	-19.73M
	Net Income Common Stockholders
-11.26M	-14.41M	-16.05M	-24.23M	-21.14M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
―	―	―	―	―
	Total Assets
19.54M	5.51M	64.66M	41.70M	49.01M
	Total Debt
2.05M	361.00K	2.35M	2.53M	2.94M
	Net Debt
-9.78M	-1.22M	-19.63M	-27.91M	-33.59M
	Total Liabilities
4.43M	7.13M	12.48M	10.79M	12.98M
	Stockholders Equity
―	―	―	―	―
Cash Flow		Free Cash Flow
-13.78M	-11.59M	-26.45M	-23.42M	25.51M
	Operating Cash Flow
-13.72M	-11.64M	-24.98M	-23.37M	25.58M
	Investing Cash Flow
―	―	―	―	―
	Financing Cash Flow
―	―	―	―	―

Notable Labs Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NTBLQ, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.35, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.42 is Neutral, neither overbought nor oversold. The STOCH value of 32.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NTBLQ.

Notable Labs Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	53 Neutral	$5.24B	3.32	-44.36%	6.63%	16.78%	-0.12%
GRI	45 Neutral	$3.29M	―	-468.00%	―	―	98.55%
ONCO	33 Underperform	$2.09M	―	-237.69%	―	―	-97.16%
NTBLQ	30 Underperform	$966.00	―	-74.53%	―	―	―
SLRX	30 Underperform	$2.30M	―	-300.16%	―	―	79.57%
PCSA	29 Underperform	$2.88M	―	-192.72%	―	―	56.26%
QNRX	25 Underperform	$5.12M	―	-138.80%	―	―	42.26%